Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.

Literature DB >> 32699482

Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.

Kevin Cowart¹.

Abstract

Entities: Gene

Year: 2020 PMID： 32699482 PMCID： PMC7364465 DOI： 10.2337/cd19-0061

Source DB: PubMed Journal: Clin Diabetes ISSN： 0891-8929

× No keyword cloud information.

41 in total

Review 1. Contributions of fasting and postprandial glucose to hemoglobin A1c.

Authors: Louis Monnier; Claude Colette
Journal: Endocr Pract Date: 2006 Jan-Feb Impact factor: 3.443

2. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors: Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal: N Engl J Med Date: 2016-09-15 Impact factor: 91.245

3. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

Authors: Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal: Endocr Pract Date: 2019-01 Impact factor: 3.443

4. Insulin for type 2 diabetes: How and when to get started.

Authors: Jay H Shubrook
Journal: J Fam Pract Date: 2014-02 Impact factor: 0.493

Review 5. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.

Authors: Se Hee Min; Jeong-Hwa Yoon; Seokyung Hahn; Young Min Cho
Journal: Diabetes Metab Res Rev Date: 2016-06-08 Impact factor: 4.876

6. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

Authors: Hans U Janka; Gerd Plewe; Matthew C Riddle; Christine Kliebe-Frisch; Matthias A Schweitzer; Hannele Yki-Järvinen
Journal: Diabetes Care Date: 2005-02 Impact factor: 19.112

3. Prevalence of and Characteristics Associated With Overbasalization Among Patients With Type 2 Diabetes Using Basal Insulin: A Cross-Sectional Study.

Authors: Kevin Cowart; Wendy H Updike; Rashmi Pathak
Journal: Clin Diabetes Date: 2021-04

3 in total

Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.

Review 1. Contributions of fasting and postprandial glucose to hemoglobin A1c.

2. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

3. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

4. Insulin for type 2 diabetes: How and when to get started.

Review 5. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.

6. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

Review 7. Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target!

Review 8. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.

9. Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.

Review 10. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.

1. Practicable Measurement and Identification of Overbasalization.

2. The Clinical Definition of Overbasalization.

3. Prevalence of and Characteristics Associated With Overbasalization Among Patients With Type 2 Diabetes Using Basal Insulin: A Cross-Sectional Study.